Targovax to host Capital Markets Day 15 October 2018, in Oslo, Norway

Presentation of full TG01 phase I/II clinical trial results in resected pancreatic cancer, by Professor Daniel Palmer

Update on the TG mutRAS neoantigen vaccine development strategy

Review of recent ONCOS-102 interim data in melanoma and mesothelioma

Oslo, Norway, 4 October 2018 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, announces that it will host a Capital Markets Day in Oslo on Monday 15 October 2018, from 08:30 – 10:30 

The event will include a presentation by a world leading expert on pancreatic cancer, Professor Daniel Palmer, who is the Chair of Medical Oncology at the University of Liverpool and Clatterbridge Cancer Centre. Professor Palmer has been involved in a number of large international clinical studies in pancreatic cancer, and was the Principal Investigator of Targovax’s TG01 phase I/II trial in resected pancreatic cancer, in combination with adjuvant gemcitabine. Top-line survival data from the trial were released in May 2018 (see press release here) and at the upcoming event Professor Palmer will present the full study results.

Øystein Soug, CEO of Targovax, will give an update on the TG mutRAS neoantigen vaccine development strategy.

There will also be an update on the ongoing ONCOS oncolytic virus program, including a review of recent interim read-outs from the ONCOS-102 clinical trials in mesothelioma and melanoma, by Magnus Jäderberg, CMO of Targovax.

Event venue: Hotel Continental, Oslo, Norway
Date: 15 October 2018
Time: 08:30 – 10:30 CET

A live webcast of the symposium will be available in the Events and Presentations section of the Targovax website.

To register for the event, please contact renate.birkeli@targovax.com.

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax@fticonsulting.com

About Targovax

Activating the patient's immune system to fight cance

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It is used as a therapeutic cancer vaccine and has been shown to activate the immune system to generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced both local and systemic innate and adaptive immune activation, which has been associated with clinical benefit. ONCOS-102’s lead indication is mesothelioma, where the virus is currently being tested in a randomized phase II trial, with a phase Ib safety lead-in cohort. Another trial, in advanced melanoma, is expected to produce important proof of concept data for checkpoint inhibitor refractory patients within the next 6-12 months.

Targovax is also developing a neo-antigen cancer vaccine targeting tumors that express mutated forms of RAS - mutations known to drive cancer. The TG vaccine program has shown a signal of efficacy in a 32-patient trial with TG01 in resected pancreatic cancer. A next generation product candidate, TG02 is currently tested as monotherapy and will also be tested in combination with Keytruda® (an anti-PD1 Check point inhibitor, CPI).